EGFR and non-small cell lung carcinoma: By means of an in vitro approach, the miR-184 and miR-22-3p targeting resulted in a desensitization of EGFR-mutated NSCLC cells to Osimertinib, a potent tyrosine kinase inhibitor commonly used in EGFR-mutated patients.